V-9302

Selective inhibitor of the alanine-serine-cysteine transporter 2 (ASCT2 or SLC1A5; IC50 = 9.0 µM rat and 9.6 µM human) .1,2 It inhibited the uptake of both glutamine and possibly other amino acids in human cancer cells and reduced in vitro viability by at least 20% in more than half of 29 cancer cell lines screened.2 V-9302 decreased mTOR activity, elevated autophagy, and increased oxidative stress in multiple animal cancer models.2-5